
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
created: Oct. 10, 2025, 7 p.m. | updated: Oct. 11, 2025, 4:31 p.m.
FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Before receiving UZEDY, tell your healthcare provider about all your medical conditions, including if you:have had Neuroleptic Malignant Syndrome.
1 week, 4 days ago: News Ticker - markets.businessinsider.com